{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:25:51Z","timestamp":1792578351996,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Growing evidence suggests that enhancement of the tumor immune response contributes to the antitumor activity of CDK4\/6 inhibitors (CDK4\/6i), but the role of pretreatment tumor immune microenvironment is not clear. We retrospectively investigated in patients with HR+\/HER2- advanced breast cancer receiving CDK4\/6i and endocrine therapy whether pretreatment stromal tumor infiltrating lymphocytes (sTILs) were associated with outcome. A total of 100 patients were evaluable 53 treated with palbociclib, 44 with ribociclib and 3 with abemaciclib. Tumors were classified as sTILs positive (sTILs+) when sTILs were \u2265\u200910%. 58 tumors were sTILs negative (sTILs-) and 42 sTILs+. sTILs were not associated with any outcome overall and in the ribociclib cohort. Conversely, patients treated with palbociclib and sTILs+ tumors experienced a statistically significant improved overall survival (mOS Not Reached vs. 41.1 months,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u2009.038) and a reduced risk of visceral progression (24 vs. 8 patients\n                    <jats:italic>p<\/jats:italic>\n                    =.0048) as compared with patients with sTILs- tumors. Pretreatment sTILs levels were associated with outcome in patients treated with palbociclib. Given the lack of interaction between treatment and sTILs our findings warrant validation in larger, independent cohorts and if confirmed propose sTILs as a simple and reproducible biomarker to aid patient selection for palbociclib.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-40616-1","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T18:04:42Z","timestamp":1772129082000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pretreatment tumor infiltrating lymphocytes and outcome in patients with HR+\/HER2- advanced breast cancer treated with CDK4\/6 inhibitors"],"prefix":"10.1038","volume":"16","author":[{"given":"Rosalba","family":"Torrisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Pancetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Carnaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Basilico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Gerosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Saltalamacchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Vita","family":"San\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethania","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"40616_CR1","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari, A. et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann. Oncol. 32, 1475\u20131495. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019 (2021).","journal-title":"Ann. Oncol."},{"issue":"471","key":"40616_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature23465","volume":"54","author":"S Goel","year":"2017","unstructured":"Goel, S. et al. CDK4 \/ 6 inhibition triggers anti -tumour immunity. Nature 54 (471), 47\u201345. https:\/\/doi.org\/10.1038\/nature23465 (2017).","journal-title":"Nature"},{"key":"40616_CR3","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1158\/1078-0432.CCR-18-1967","volume":"25","author":"JL Teh","year":"2019","unstructured":"Teh, J. L. & Aplin A.Arrested developments: CDK4\/6 inhibitors resistance and alterations in the tumor immune microenvironment. Clin. Cancer Res. 25, 921\u2013927. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1967 (2019).","journal-title":"Clin. Cancer Res."},{"key":"40616_CR4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","volume":"8","author":"J Deng","year":"2018","unstructured":"Deng, J. et al. CDK 4\/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov. 8, 216\u2013233. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0915 (2018).","journal-title":"Cancer Discov"},{"key":"40616_CR5","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1016\/j.celrep.2018.02.053","volume":"22","author":"DA Schaer","year":"2018","unstructured":"Schaer, D. A. et al. The CDK4\/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade. Cell. Rep. 22, 2978\u20132994. https:\/\/doi.org\/10.1016\/j.celrep.2018.02.053 (2018).","journal-title":"Cell. Rep."},{"key":"40616_CR6","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an Internationa TILs Working Group 2014. Ann. Oncol. 26, 259\u2013271. https:\/\/doi.org\/10.1093\/annonc\/mdu450 (2015).","journal-title":"Ann. Oncol."},{"key":"40616_CR7","doi-asserted-by":"publisher","first-page":"115219","DOI":"10.1016\/j.ejca.2024.115219","volume":"217","author":"P Tolosa","year":"2025","unstructured":"Tolosa, P. et al. Efficacy outcomes of CDK4\/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive\/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study. Eur. J. Cancer. 217, 115219. https:\/\/doi.org\/10.1016\/j.ejca.2024.115219 (2025).","journal-title":"Eur. J. Cancer"},{"key":"40616_CR8","doi-asserted-by":"publisher","first-page":"e622","DOI":"10.1093\/oncolo\/oyad337","volume":"29","author":"F Schettini","year":"2024","unstructured":"Schettini, F. et al. CDK4\/6-Inhibitors Versus Chemotherapy in Advanced HR+\/ HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial. Oncologist 29, e622\u2013e634. https:\/\/doi.org\/10.1093\/oncolo\/oyad337 (2024).","journal-title":"Oncologist"},{"key":"40616_CR9","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.3390\/ijms25031498","volume":"25","author":"R Torrisi","year":"2024","unstructured":"Torrisi, R. et al. Identification of a Panel of miRNAs Associated with Resistance to Palbociclib and Endocrine Therapy. Int. J. Mol. Sci. 25, 1498. https:\/\/doi.org\/10.3390\/ijms25031498 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"40616_CR10","doi-asserted-by":"publisher","unstructured":"El Bairi, K. et al. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group NPJ Breast Cancer. ; 7:150. (2021). https:\/\/doi.org\/10.1038\/s41523-021-00346-1","DOI":"10.1038\/s41523-021-00346-1"},{"key":"40616_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.semcancer.2017.10.003","volume":"52","author":"MV Dieci","year":"2018","unstructured":"Dieci, M. V. et al. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Semin Cancer Biol. 52, 16\u201325. https:\/\/doi.org\/10.1016\/j.semcancer.2017.10.003 (2018).","journal-title":"Semin Cancer Biol."},{"key":"40616_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert, C. et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 19, 40\u201350. https:\/\/doi.org\/10.1016\/S1470-2045(17)30904-X (2018).","journal-title":"Lancet Oncol."},{"key":"40616_CR13","doi-asserted-by":"publisher","unstructured":"Skriver, S. K., Jensen, M-B., Knoop, A. S., Ejlertsen, B. & Laenkholm, A-V. Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor positive breast cancer: analysis from a nationwide phase II DBCG trial Breast. Cancer Res. 2020 22:46 https:\/\/doi.org\/10.1186\/s13058-020-01285-8","DOI":"10.1186\/s13058-020-01285-8"},{"key":"40616_CR14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-x","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper, M. & Smith, T. L. A note of quantifying follow-up in studies of failure time. Control Clin. Trials. 17, 343\u2013346. https:\/\/doi.org\/10.1016\/0197-2456(96)00075-x (1996).","journal-title":"Control Clin. Trials"},{"key":"40616_CR15","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.clbc.2022.06.004","volume":"22","author":"IA Vathiotis","year":"2022","unstructured":"Vathiotis, I. A. et al. Immune checkpoint blockade in hormone receptor-psitive breast cancer: resistance mechanisms and future perspectives. Clin. Breast Cancer. 22, 642\u2013649. doi.org\/10.1016\/j. clbc.2022.06.004 (2022).","journal-title":"Clin. Breast Cancer"},{"issue":"Supplement 4","key":"40616_CR16","doi-asserted-by":"publisher","first-page":"103247","DOI":"10.1016\/j.esmoop.2024.103247","volume":"9","author":"ML S\u00e1nchez-Le\u00f3n","year":"2024","unstructured":"S\u00e1nchez-Le\u00f3n, M. L. et al. 225P Impact of cyclin inhibitors (CDK4\/6i) on immune cell populations in first-line treated metastatic breast cancer (mBC) patients. ESMO Open. 9 (Supplement 4), 103247. doi.org\/10.1016\/j. esmoop.2024.103247 (2024).","journal-title":"ESMO Open."},{"key":"40616_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejca.2021.11.025","volume":"162","author":"CA Peuker","year":"2022","unstructured":"Peuker, C. A. et al. Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptorpositive breast cancer-findings from the RIBECCA trial. Eur. J. Cancer. 162, 45\u201355. https:\/\/doi.org\/10.1016\/j.ejca.2021.11.025 (2022).","journal-title":"Eur. J. Cancer"},{"key":"40616_CR18","doi-asserted-by":"publisher","first-page":"104634","DOI":"10.1016\/j.critrevonc.2025.104634","volume":"208","author":"R Torrisi","year":"2025","unstructured":"Torrisi, R. et al. Beyond endocrine-based therapy for HR+\/HER2- advanced breast cancer: what before chemotherapy? A glimpse into the future. Crit. Rev. Oncol. Hematol. 208, 104634. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104634 (2025).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"40616_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-025-02226-9","volume":"24","author":"L Luo","year":"2025","unstructured":"Luo, L. et al. Single- cell RNA sequencing identifies molecular biomarkers predicting late progression to CDK4\/6 inhibition in patients with HR+\/HER2- metastatic breast cancer. Mol. Cancer. 24, 48. https:\/\/doi.org\/10.1186\/s12943-025-02226-9 (2025).","journal-title":"Mol. Cancer"},{"key":"40616_CR20","unstructured":"Sanati, S. et al. Tumor infiltrating lymphocytes (TILs) as a biomarker for resistance to palbociclib (Pal) in the NeoPalAna trial. Presented at: 2017 SABCS. San Antonio, TX, US. Cancer Res. ; 78(4 Suppl. 1). (2018)."},{"key":"40616_CR21","unstructured":"Maruthi, V. K. et al. CDK4\/6 Inhibitors for Metastatic HR+\/HER2-Breast Cancer: Clinico-Pathological Analysis for Determinants of Response. Presented at: 111th Annual Meeting of the United States and Canadian Academy of Pathology, USCAP 2022. Los Angeles, CA United States. Mod Pathol. ;35(Suppl. 2):136-8. (2022)."},{"key":"40616_CR22","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1038\/s41467-025-56279-x","volume":"16","author":"JI Griffiths","year":"2025","unstructured":"Griffiths, J. I. et al. Cellular interactions within the immune microenvironment underpins resistance to cell cycle inhibition in breast cancers. Nat. Commun. 16, 2132. https:\/\/doi.org\/10.1038\/s41467-025-56279-x (2025).","journal-title":"Nat. Commun."},{"key":"40616_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41523-024-00625-7","volume":"10","author":"T Pascual","year":"2024","unstructured":"Pascual, T. et al. Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy. NPJ Breast Cancer. 10, 20. https:\/\/doi.org\/10.1038\/s41523-024-00625-7 (2024).","journal-title":"NPJ Breast Cancer"},{"issue":"6","key":"40616_CR24","doi-asserted-by":"publisher","first-page":"oyaf123","DOI":"10.1093\/oncolo\/oyaf123","volume":"30","author":"F Jacobs","year":"2025","unstructured":"Jacobs, F. et al. Pre-existing and emerging immune-mediated diseases in patients with breast cancer undergoing cyclin-dependent kinases 4\/6 inhibitors and endocrine therapy. Oncologist 30 (6), oyaf123. https:\/\/doi.org\/10.1093\/oncolo\/oyaf123 (2025).","journal-title":"Oncologist"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40616-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40616-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40616-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T08:41:57Z","timestamp":1775119317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40616-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["40616"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-40616-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"7 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RT, LG, SV, VB, RP, RG, MVS, BF do not declare competing interestsCC advisory board (Roche) outside the submitted workAS: Advisory Board: Bristol-Myers-Squibb (BMS), Servier, Gilead, Pfizer, Eisai, Bayer, Merck Sharp and Dohme (MSD). Consultancy: Arqule, Sanofi, Incyte. Speaker\u2019s Bureau: Takeda, BMS, Roche, Abb-Vie, Amgen, Celgene, Servier, Gilead, AstraZeneca, Pfizer, Arqule, Lilly, Sandoz, Eisai, Novartis, Bayer, MSD (all outside the submitted work).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Institutional Ethical Committee of Humanitas Research Hospital (n 22\/25, 22.04.25). This study complied with all relevant ethical regulations regarding patient data, in line with ethical norms and standards in the Declaration of Helsinki. All patients gave their informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"11161"}}